Viking Therapeutics (NASDAQ: VKTX ) is underway with phase 3 work of its incretin for weight loss and diabetes, VK2735, which could mean there is a bit of a wait for the next high impactScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure:I/we have no stock, option or similar derivative pos ...